Valuation: Resverlogix Corp.

Market Cap 2.17Cr 1.53Cr 1.36Cr 1.27Cr 1.15Cr 146.91Cr 2.2Cr 15Cr 5.94Cr 75Cr 5.73Cr 5.6Cr 240.32Cr P/E 2024
-1.38x
P/E 2025 -2.68x
Enterprise Value 11Cr 7.55Cr 6.7Cr 6.27Cr 5.71Cr 726.55Cr 11Cr 76Cr 29Cr 370.02Cr 28Cr 28Cr 1.19TCr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
60.44%
Yield 2024 *
-
Yield 2025 -
1 day-8.47%
1 week+3.67%
Current month-8.53%
1 month-12.57%
3 months+3.32%
6 months-20.61%
Current year-16.17%
1 week 0.06
Extreme 0.05822
0.07
1 month 0.06
Extreme 0.05822
0.07
Current year 0.05
Extreme 0.0492
0.1
1 year 0.05
Extreme 0.0492
0.1
3 years 0.02
Extreme 0.023
0.21
5 years 0.02
Extreme 0.023
0.65
10 years 0.02
Extreme 0.023
4.14
Manager TitleAgeSince
Chief Executive Officer - 25/04/2003
Director of Finance/CFO 78 29/10/2009
Chief Tech/Sci/R&D Officer - 15/08/2022
Director TitleAgeSince
Chairman - 04/04/2016
Director/Board Member 56 15/10/2009
Director/Board Member 66 29/09/2010
Change 5-day change 1-year change 3-year change Capi.($)
-8.47%+3.67% - - 2.17Cr
+4.16%+3.04%+49.37%+94.17% 7.44TCr
-0.97%-1.40%+24.61%+78.46% 5.93TCr
+1.14%-0.74%+4.17%+34.36% 4.71TCr
-3.02%-5.20%+27.94%+32.51% 4.29TCr
+0.31%+3.02%+348.95%+643.82% 4.41TCr
-1.96%-0.33%+7.04%+99.46% 4.08TCr
+3.32%+3.49%+10.10%+51.23% 3.08TCr
-2.68%+2.92%+29.63%+22.72% 2.93TCr
-4.86%-10.66%-26.27%+330.06% 2.37TCr
Average -1.31%-0.52%+52.84%+154.09% 4.36TCr
Weighted average by Cap. +0.04%-0.32%+58.02%+145.78%

Financials

2024 2025
Net sales - -
Net income -76.35L -53.58L -47.59L -44.5L -40.55L -52Cr -77.4L -5.38Cr -2.08Cr -26Cr -2.01Cr -1.97Cr -84Cr -77.67L -54.5L -48.41L -45.27L -41.26L -52Cr -78.74L -5.48Cr -2.12Cr -27Cr -2.05Cr -2Cr -86Cr
Net Debt 8.19Cr 5.75Cr 5.1Cr 4.77Cr 4.35Cr 553.16Cr 8.3Cr 58Cr 22Cr 281.72Cr 22Cr 21Cr 904.85Cr 8.58Cr 6.02Cr 5.35Cr 5Cr 4.56Cr 579.64Cr 8.7Cr 60Cr 23Cr 295.2Cr 23Cr 22Cr 948.16Cr
Logo Resverlogix Corp.
Resverlogix Corp. is a Canada-based late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. The Company focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The Company's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. It partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Employees
-
Date Price Change Volume
01/26/01 $0.0622 -8.47% 3,133
30/26/30 $0.0680 -1.88% 1,000
25/26/25 $0.0693 +15.50% 610
24/26/24 $0.0600 -6.54% 40,000
23/26/23 $0.0642 +1.26% 23,000